Search Results (1,796)

We developed a solvent-suppressed ¹H nuclear magnetic resonance (NMR) method for the quantitative analysis of the components of rotigotine prolonged-release microspheres prepared for injection. Dimethyl terephthalate was used as an internal standard and dimethylsulfoxide -d₆ as the solvent. The analysis was performed using a Bruker Avance III HD 600 MHz NMR spectrometer, employing the noesygppr1d pulse sequence at a controlled temperature of 25 °C. Nuclear magnetic resonance spectra were acquired with a relaxation delay time (D1) of 40 s to simultaneously determine the content of rotigotine and the excipients mannitol and stearic acid in the rotigotine prolonged-release microspheres. Using the proposed approach, we successfully quantified the active pharmaceutical ingredient rotigotine and excipients in the prolonged-release microspheres. This method demonstrated excellent linearity, high precision, and strong repeatability. The solvent-suppressed ¹H NMR method developed in this study allows for the simultaneous quantification of rotigotine and the key excipients mannitol and stearic acid in the prolonged-release microspheres. This approach is accurate, simple, efficient, and environmentally friendly. Full article

Vitamin D is increasingly recognized as a key regulator of epithelial barrier integrity and mucosal immune homeostasis, with implications extending far beyond skeletal health. Through the vitamin D receptor (VDR), vitamin D regulates epithelial cohesion, innate immune responses, and tight-junction gene expression. This review explores the multifactorial role of vitamin D in modulating inflammation and preserving tissue barriers, with particular emphasis on its effects on tight junction (TJ) regulation and disease states characterized by barrier dysfunction, namely atopic dermatitis, psoriasis, inflammatory bowel disease (IBD), and celiac disease. In these settings, vitamin D/VDR signaling exerts protective actions by enhancing barrier structure, suppressing Th1/Th17-driven inflammation, modulating the gut and skin microbiome, and promoting epithelial repair. Animal studies and clinical data suggest that vitamin D supplementation can restore TJ expression, reduce disease activity, and improve clinical outcomes in both intestinal and dermatologic diseases. In the cardiovascular system, the role of vitamin D remains complex. While vitamin D influences endothelial function, insulin sensitivity, and systemic inflammation, supplementation trials yield mixed results, indicating a need for individualized approaches. Overall, this review synthesizes mechanistic, translational, and clinical data supporting vitamin D as a crucial modulator of barrier integrity and inflammation. These findings highlight its therapeutic relevance in chronic diseases characterized by immune dysregulation and epithelial disruption. Full article

Resveratrol (RVT) is a plant-derived polyphenol found in traditional medicinal species such as Veratrum grandiflorum and Polygonum cuspidatum, known for their bioactive secondary metabolites. This study evaluates the anti-obesity effects of RVT alone and in combination with orlistat (OLT), a pharmaceutical lipase inhibitor, in a high-fat diet-induced obesity model in rats. Female Sprague-Dawley rats were assigned to receive RVT, OLT, a combination of both, or no treatment, over a four-week period. The combination of RVT and OLT led to a significant reduction in body weight gain and improvement in lipid profiles, including decreased LDL cholesterol. Additionally, the combination ameliorated liver enzyme elevations associated with obesity-related hepatic stress. These findings demonstrate that resveratrol potentiates orlistat’s pharmacological efficacy and highlights the therapeutic potential of bioactive compounds from medicinal plants in metabolic disease management. This study supports further development of plant-based pharmacological agents and synergistic formulations for the treatment of obesity and associated comorbidities. Full article

Background/Objectives: In India, according to the National Family Health Survey (NFHS-5), 36% of children under five years old are stunted, 19% are wasted, and 32% are underweight, indicating widespread undernutrition. Methods: A randomized controlled trial was conducted between August 2023 and May 2024 (CTRI/2023/04/051566), enrolling 223 undernourished Indian children, randomly assigned to the oral nutritional supplement (ONS) + dietary counseling (DC) (n = 111) arm or the dietary counseling (DC) arm (n = 112). This study recruited both male and female subjects with picky eating habits and with height-for-age (HAP) and weight-for-height percentiles (WHP) below the 25th percentile according to the WHO Growth Standards and Growth Reference. Outcomes assessed were anthropometric indices, dietary intake, sick days, and nutrient adequacy. Data were analyzed using ANCOVA, with statistical significance at p < 0.05. Results: At 6 months, the ONS + DC group showed significant improvements compared to DC in HAP (12.1 vs. −0.4, LS Mean difference [95% CI], 13.3 [11.13, 15.48], p < 0.0001), and WAP (9.7 vs. 2.3, LS Mean difference [95% CI] 7.9 [5.07, 10.78], p < 0.0001). MUACP significantly increased in the ONS + DC group (11.1 vs. −1.0 in DC, LS Mean difference [95% CI], 11.1 [5.28, 16.99], p < 0.0001). Dietary intake of carbohydrates, proteins, and energy was significantly higher in the ONS + DC group at 3 months, with sustained improvements at 6 months. By 6 months, the ONS + DC group showed a significantly higher protein-to-energy intake ratio compared to the DC group (0.0027 vs. −0.0003, LS Mean difference [95% CI] 0.00224 [0.00025, 0.00423], p = 0.0204). Conclusions: The addition of ONS + DC significantly improved linear catch-up growth outcomes in children at risk of undernutrition as a result of improved energy and nutrient intake and a higher protein-to-energy ratio. Full article

In humans, the bioactivity of polyphenols is highly dependent on dose intake and their interactions with the gastrointestinal tract and gut microbiota, which metabolize polyphenols into bioactive or inactive derivatives. Polyphenols are only partially absorbed in the small intestine, where enzymatic hydrolysis releases aglycone forms that may cross the gut barrier. A significant proportion of polyphenols escapes absorption and reaches the colon, where resident microbes convert them into simpler phenolic metabolites. Such molecules are often more bioavailable than the parent compounds and can enter systemic circulation, leading to distant effects. Although higher polyphenol consumption has been associated with preventive and therapeutic outcomes, even low intake or poor intestinal absorption may still confer benefits, as polyphenols in the colon can positively modulate gut microbiota composition and function, contributing to favorable shifts in the microbial metabolome. These interactions can influence host metabolic, immune, and neurological pathways, particularly through the gut–liver–brain axis. To provide a comprehensive understanding of these relationships, this review examines the dose-related activity of polyphenols, their microbiota-mediated biotransformation, their bioavailability, and the health effects of their metabolites, while also presenting a comparative overview of key studies in the field. We underscore the importance of integrating microbiome and polyphenol research to recapitulate and contextualize the health benefits of dietary polyphenols. Full article

Background: Pain is a multifaceted and debilitating symptom in patients with gastrointestinal cancer, especially those undergoing surgical resection followed by chemotherapy. The interplay between inflammatory, neuropathic, and psychosocial components often renders conventional analgesia insufficient. Psychobiotics—probiotic strains with neuroactive properties—have recently emerged as potential modulators of pain perception through neuroimmune and gut–brain axis pathways. Methods: This post hoc analysis is based on the ProDeCa randomized, placebo-controlled trial, which originally aimed to assess the psychotropic effects of a four-strain psychobiotic formulation in postoperative gastrointestinal cancer patients receiving chemotherapy. In the current analysis, we evaluated changes in pain perception among non-depressed and depressed participants, who received either psychobiotics or placebo, along with standard analgesic regimes. Pain was assessed at baseline, after a month of treatment, and at follow-up, 2 months thereafter, using the Short-Form McGill Pain Questionnaire (SF-MPQ), capturing both sensory and affective components, as well as with the Present Pain Intensity and the VAS scores. Results: Psychobiotic-treated participants—particularly the non-depressed ones—exhibited a significant reduction in both quantitative and qualitative pain indices over time compared with placebo-treated ones. Improvements were noted in total pain rating index scores, sensory and affective subscales, and present pain intensity. These effects were sustained up to 2 months after intervention. In contrast, placebo groups demonstrated worsening in pain scores, probably influenced by ongoing chemotherapy and disease progression. The analgesic effect was less pronounced but still observable in the subgroup with symptoms of depression. Conclusions: Adjunctive psychobiotic therapy appears to beneficially modulate pain perception in gastrointestinal oncology patients receiving chemotherapy, with the most pronounced effects being in non-depressed individuals. These findings suggest psychobiotics as a promising non-opioid add-on for comprehensive cancer pain management and support further investigation in larger pain-targeted trials. Full article

Background/Objectives: Pharmacists’ roles are shifting from dispensing medications to managing chronic diseases and prevention. Diabetes is a growing public health issue requiring early detection and management, where pharmacists can play a key role. The SMART Pharmacist Program promotes continuing education and expanded care, and a nationwide blood sugar screening campaign in North Macedonia was conducted to evaluate the impact of pharmacists in detecting undiagnosed diabetes and supporting glycemic control. Methods: This descriptive observational cross-sectional study was conducted mainly on 14 November 2024, in 98 community pharmacies across 14 cities. Participants over 18 years old were recruited via voluntary sampling. A total of 998 measurements were performed on the campaign day, with additional screening extending to 24 January 2025, totaling 1085 participants. Blood glucose was measured by finger prick testing and classified according to national and NICE guidelines. A structured questionnaire collected demographic, medical, and lifestyle data. Results: Among 1085 participants (65.1% female, mean age 57.6 ± 14.5 years), 258 (23.8%) had diagnosed diabetes, mostly Type 2 (226; 20.8%), while 827 (76.2%) were undiagnosed. Males had 1.7 times higher odds of diabetes. Diabetes prevalence correlated with physical inactivity, higher BMI, smoking, and chronic diseases. Among the undiagnosed, 17.8% were prediabetic and 4.3% diabetic. Of diagnosed patients, 57% had well-controlled and 42% poorly controlled diabetes. Metformin-based therapies were most common for Type 2 diabetes. Conclusions: Community pharmacists can effectively support early detection of diabetes and identify patients with suboptimal glycemic control, enhancing diabetes management in the community. Full article

The healthcare industry faces mounting pressure to enhance efficiency and accuracy in logistics operations. Despite its critical role, the sector demonstrates a low adoption rate of logistics automation, with the investment ratio at 14.9%, significantly lower than the industrial average of 18%. This study explores the current state and strategic application of logistics automation in healthcare through 20 in-depth interviews with stakeholders across manufacturers, wholesalers, hospitals, clinics, and pharmacies in South Korea. Analysis revealed that automation adoption is largely contingent on two key factors: annual order volumes and inventory complexity. Companies handling over 100,000 order lines annually and managing over 1000 SKUs were more likely to have adopted or planned automation systems such as AS/RSs, AMRs, or Cube-based AS/RS. The research culminates in a directional map that aligns automation strategies with operational scale and product characteristics. This study contributes novel empirical insights into the fragmented healthcare logistics sector, offering actionable guidance for phased automation implementation based on contextual constraints and stakeholder typologies. Full article

The brewing industry generates vast amounts of by-products of biotic and abiotic nature that require proper handling to reduce their environmental footprint annually. Simultaneously, and in alignment with the current circular economy dynamics, there is a growing trend towards the valorization of such by-products, through upcycling and/or repurposing. Biotic by-products are a low-cost source of valuable compounds, such as proteins, carbohydrates, lipids and phenolic compounds, which, with adequate recovery methods, can be used in various industries, e.g., agro-food and pharma, among others, where their bioactive and physical-chemical properties can be harnessed effectively. Abiotic by-products are increasingly valorized through pathways that prioritize material recovery and functional reuse. This work aims to address the most relevant by-products from brewing by providing a broad perspective that abridges their sources alongside the manufacturing chain, the composition of the different by-products, and current and foreseen handling and valorization strategies. Full article

This study explores the antioxidant potential and delivery performance of five structurally distinct cannabinoids, with a particular focus on cannabinol (CBN). Comprehensive structural characterization using mass spectrometry (MS) and nuclear magnetic resonance (NMR) revealed key molecular features relevant to antioxidant function. Among the tested compounds, CBN exhibited the most potent and balanced radical scavenging activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH), hydroxyl, and superoxide radicals. Based on these findings, CBN was selected for formulation into soy lecithin liposomes. The resulting CBN-loaded liposomes displayed favorable colloidal properties, with an average size of approximately 122.9 ± 0.4 nm. Results indicating increased membrane order upon CBN incorporation suggest enhanced stability of the liposomal bilayer. Antioxidant activity assays showed that CBN-loaded liposomes retain significant radical scavenging capacity, though with a moderate reduction compared to free CBN. EPR imaging further demonstrated superior diffusion of liposomal CBN through a gelatin-based semi-solid model compared to the control solution. While the current model does not replicate skin architecture, it provides a cost-effective and reproducible platform for early-stage screening of formulation mobility. These results position CBN-loaded liposomes as a promising candidate for dermal antioxidant applications, combining favorable physicochemical properties with enhanced diffusion behavior. Full article

Background: GSK3β is an intracellular regulatory kinase that is dysregulated in multiple tissues in Type 1 myotonic dystrophy (DM-1). Tideglusib inhibits GSK3β activity in preclinical models of DM-1 and promotes cellular maturation, normalising aberrant molecular and behavioural phenotypes. It is currently in clinical development for the treatment of paediatric and adult patients affected by congenital and juvenile-onset DM-1. Here, we summarise the development of a population pharmacokinetic model and subsequent characterisation of influential demographic and clinical factors on the systemic exposure to tideglusib. The availability of a population PK model will allow further evaluation of age-and weight-related changes in drug disposition, supporting the dose rationale and implementation of a paediatric extrapolation plan. Methods: Given the sparse pharmacokinetic sampling scheme in patients receiving tideglusib, model development was implemented in two steps. First, data from Phase I studies in healthy elderly subjects (i.e., 1832 plasma samples, n = 54) were used to describe the population pharmacokinetics of tideglusib in adults. Then, pharmacokinetic model parameter estimates obtained from healthy subjects were used as priors for the evaluation of the disposition of tideglusib in adolescent and adult DM-1 patients (51 plasma samples, n = 16), taking into account demographic and clinical baseline characteristics, as well as food intake. Secondary pharmacokinetic parameters (AUC, C_max and T_max) were derived and summarised by descriptive statistics. Results: Tideglusib pharmacokinetics was described by a two-compartment model with first-order elimination and dose-dependent bioavailability. There were no significant differences in disposition parameters between healthy subjects and DM-1 patients. Body weight was a significant covariate on clearance and volume of distribution. Median AUC_(0–12) and C_max were 1218.1 vs. 3145.7 ng/mL∙h and 513.5 vs. 1170.9 ng/mL, following once daily doses of 400 and 1000 mg tideglusib, respectively. In addition, the time of food intake post-dose or the type of meal appeared to affect the overall exposure to tideglusib. No accumulation, metabolic inhibition, or induction was observed during the treatment period. Conclusions: Even though clearance was constant over the dose range between 400 and 1000 mg, a less than proportional increase in systemic exposure appears to be caused by the dose-dependent bioavailability, which reflects the solubility properties of tideglusib. Despite large interindividual variability in the tideglusib concentration vs. time profiles, body weight was the only explanatory covariate for the observed differences. This finding suggests that the use of weight-banded or weight-normalised doses should be considered to ensure comparable exposure across the paediatric population, regardless of age or body weight. Full article

Sexual dysfunction affects an estimated 50–70% of cancer survivors but remains underrecognized and undertreated, impacting quality of life and emotional well-being. This narrative review involves a comprehensive search of PubMed/MEDLINE, CINAHL, Scopus, Web of Science, and ScienceDirect for English-language publications (January 2010–May 2025), using combined MeSH and free-text terms for ‘sexual health’, ‘cancer’, ‘nursing’, ‘roles of nurses’, ‘immunotherapy’, ‘targeted therapy’, ‘sexual health’, ‘sexual dysfunction’, ‘vaginal dryness’, ‘genitourinary syndrome of menopause’, ‘sexual desire’, ‘body image’, ‘erectile dysfunction’, ‘climacturia’, ‘ejaculatory disorders’, ‘dyspareunia’, and ‘oncology’. We used the IMRAD (Introduction, Methods, Results, and Discussion) approach to identify 1245 records and screen titles and abstracts. Fifty studies ultimately met the inclusion criteria (original research, reviews, and clinical guidelines on oncology nursing and sexual health). Results: All the treatments contributed to reduced libido, erectile dysfunction, dyspareunia, and body image concerns, with a prevalence of 57.5% across genders. Oncology nurses can provide sex education and counseling. Barriers (limited training, cultural stigma, and the absence of protocols) hinder effective intervention. Addressing these issues through sexual health curricula, formal referral systems, and policy reforms can enhance nursing care. Future research should assess the impact of targeted nurse education and the institutional integration of sexual health into cancer care. Full article

Peri-implant disease and gingival recession may be partially attributed to inadequate keratinized tissue. Soft tissue augmentation procedures utilizing non-autologous biomaterials, such as porcine-derived collagen membranes, have been gaining prominence and exogenous crosslinking is being actively investigated to improve the collagen membrane’s stability and potential for keratinized tissue gain. The aim of this preclinical study was to evaluate the performance of a novel, crosslinked porcine collagen membrane (Zderm^TM, Osteogenics Biomedical, Lubbock, TX, USA) relative to an established, commercially available, non-crosslinked counterpart (Mucograft^®, Geistlich Pharma North America Inc., Princeton, NJ, USA) in a canine mandibular model. Bilateral split-thickness mucosal defects were created in adult beagles (n = 17), with each site receiving one membrane. Qualitative and quantitative histomorphometric analyses of groups were performed after 4, 8, and 12 weeks of healing and compared to unoperated, positive controls from the same subject. No significant differences in membrane presence were observed between Zderm^TM and Mucograft^® at 4, 8, and 12 weeks of permitted healing (p > 0.05). Similarly, the average keratinized tissue (KT) length between Zderm^TM and Mucograft^® groups was statistically equivalent across all healing times (p > 0.05). However, qualitative histological evaluation revealed greater rete ridge morphology amongst defects treated with Zderm^TM in comparison to Mucograft^®. Nevertheless, both membranes exhibited excellent biocompatibility and are well-suited for soft tissue augmentation procedures in the oral cavity. Full article

The rise of multidrug-resistant pathogens has become a serious health concern, creating an urgent need for novel therapeutic approaches. Among the compounds explored, AMPs have emerged as promising candidates due to their broad-spectrum activity and low propensity for resistance development. However, their clinical implementation is limited by improper size, in vivo instability, and toxicity. Here, we designed short analogs of CeHS-1 via (1) truncation of intact CeHS-1, (2) amino acid substitution, (3) end-tagging, and (4) C-terminal amidation. The results showed that short analogs fused with an RWW stretch exhibited stronger antibacterial activity than the parent analogs, without inducing hemolysis in human red blood cells. Among the tested AMPs, mechanistic studies revealed membrane-disruptive activity of certain peptides against Staphylococcus aureus. In silico analyses also suggested that the analogs bind DNA by aligning parallel to its grooves, where the RWW stretch is believed to contribute to interactions between arginine and tryptophan residues and nitrogenous bases through electrostatic, hydrogen bonding, and hydrophobic interactions. The short CeHS-1 analogs established here may serve as potential alternative antimicrobial agents, which should be tested in clinical trials in the future. Full article